Alexion Pharmaceuticals Inc (ALXN)

pos +0.00
Today's Range: 0.00 - 0.00 | ALXN Avg Daily Volume: 1,721,600
Last Update: 11/24/15 - 3:59 PM EST
Volume: 0
YTD Performance: -3.91%
Open: $0.00
Previous Close: $177.80
52 Week Range: $142.02 - $208.88
Oustanding Shares: 225,324,303
Market Cap: 39,650,317,599
6-Month Chart
TheStreet Ratings Grade for ALXN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 13 14
Moderate Buy 1 1 0 0
Hold 3 3 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.43 1.43 1.47 1.35
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 155.73
Price Earnings Comparisons:
ALXN Sector Avg. S&P 500
155.73 142.90 32.53
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.56% -8.42% 87.73%
Revenue 44.00 1.85 0.41
Net Income 159.80 2.75 0.55
EPS 157.30 2.46 0.51
Earnings for ALXN:
Revenue 2.23B
Average Earnings Estimates
Qtr (12/15) Qtr (03/16) FY (12/15) FY (12/16)
Average Estimate $0.92 $0.94 $4.07 $4.43
Number of Analysts 2 1 2 2
High Estimate $0.92 $0.94 $4.10 $4.46
Low Estimate $0.91 $0.94 $4.04 $4.39
Prior Year $1.13 $1.07 $4.64 $4.07
Growth Rate (Year over Year) -19.03% -12.15% -12.28% 8.72%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Oct 02, 2015 | 7:50 AM EDT
ALXN was upgraded to Overweight, Morgan Stanley said. $211 price target. Orphan drugs should not face pricing concerns and the company ...
Sep 14, 2015 | 8:09 AM EDT
ALXN was downgraded from Overweight to Equal-weight, Barclays said. $205 price target. Expects delays in Strensiq and Kanuma launches. ...
Acquisitions cut into overabundance of companies.
U.S. stocks fell for a second straight session.
Here are healthcare stocks of all shares and sizes with strong charts.
Jan 30, 2015 | 7:49 AM EST
Shares of ALXN now seen reaching $186, according to Credit Suisse. Estimates also reduced, given the company's currency headwinds. Neut...

Braving Biotech Real Money Pro($)

Do you need to pick one name?
They are prone to being whipsawed by news.
Jan 05, 2015 | 6:36 AM EST
ALXN was downgraded from Overweight to Equal-weight, Morgan Stanley said. $202 price target. Valuation call, as the company has limited...
A few stocks that could break higher.

Columnist Conversations

"Valuations on both the asset markets and the housing market in particular are unusually high at present. This...
Market holding up very well given news of downed Russian jet over Turkey today. However, it is still a very b...
Yesterday's Saudi announcement coupled with this morning's geopolitical tensions have combined to goose oil pr...
These refiners are stretching out here, the best turnover is in Valero, and we have seen some big option flow ...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.